Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5696479 | 0.79 | TSHR (0.33) | GRIK1GRIK2TSHRALDH1A1 | |
| SCHEMBL3270630 | 0.71 | HTT (0.32) | GRIK1GRIK2HTT | |
| SCHEMBL3975169 | 0.71 | THRB (0.38) | TSHRALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL29134499 | 0.69 | ALDH1A1 (0.39) | TSHRALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL11500776 | 0.67 | TSHR (0.35) | TSHRALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL10912883 | 0.67 | ALDH1A1 (0.38) | TSHRALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL23494133 | 0.66 | TSHR (0.47) | TSHRALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL3666505 | 0.66 | TSHR (0.38) | TSHRALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL9546460 | 0.64 | ALDH1A1 (0.39) | TSHRALDH1A1TP53CYP3A4MAPK1 | |
| SCHEMBL7652425 | 0.64 | ALDH1A1 (0.39) | TSHRALDH1A1TP53CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5155156-A | Mixed with oil; flocculants for papermaking, oil recovery, sewage treatment | SCANLEY CLYDE S (US) | 1992-10-13 | — | — | US | claimed |
| EP-1663139-A1 | CONDITIONING COMPOSITION COMPRISING CATIONIC CROSSLINKED THICKENING POLYMER AND NONIONIC SURFACTANT | THE PROCTER & GAMBLE COMPANY (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050002892-A1 | Conditioning composition comprising cationic crosslinked thickening polymer and nonionic surfactant | THE PROCTER & GAMBLE COMPANY | 2005-01-06 | — | — | US | disclosed |
| WO-2004108101-A1 | CONDITIONING COMPOSITION COMPRISING CATIONIC CROSSLINKED THICKENING POLYMER AND NONIONIC SURFACTANT | THE PROCTER & GAMBLE COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
| WO-2004035016-A1 | CONDITIONING COMPOSITION COMPRISING CATIONIC CROSSLINKED POLYMER | THE PROCTER & GAMBLE COMPANY (US) | 2004-04-29 | — | — | WO | disclosed |
| US-5250586-A | Dispersing particles in oil immiscible with polymer, then converting first dispersion to a second dispersion, the second having a lower content of surfactant than the first | SCANLEY CLYDE S (US) | 1993-10-05 | — | — | US | disclosed |
| US-5155156-A | Mixed with oil; flocculants for papermaking, oil recovery, sewage treatment | SCANLEY CLYDE S (US) | 1992-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050002892-A1 | Conditioning composition comprising cationic crosslinked thickening polymer and nonionic surfactant | CUTA, PCNA, DSG1 | GRIK1 924/4885GRIK2 1222/4885TSHR 4428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.